Clinical trial · Interventional
Feasibility of Fluorescence Imaging With Bevacizumab-800CW During Bronchoscopy
Feasibility of Fluorescence Imaging With Bevacizumab-800CW During Bronchoscopy in Patients With a Pulmonary Lesion Considered to be Malignant - DEFLECT I
NCT06809946CI-TRIAL-00106804DEFLECT Inot yet recruitingPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
In this feasibility study, bronchoscopy will be combined with fluorescence molecular imaging using the near-infrared fluorescence (NIRF) tracer bevacizumab-800CW for assessment of pulmonary lesions and/or lymph nodes considered to be malignant.
Conditions
Conditions (4)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Lung Neoplasms | Lung Neoplasm | ONTOLOGY_EXACT | 0.98 |
| Lymph Node Involvement | — | UNRESOLVED | — |
| Pulmonary Neoplasms | — | UNRESOLVED | — |
| Pulmonary Nodule | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| injection with 15 mg bevacizumab-800CW before bronchoscopy | Drug | — | UNRESOLVED |
| injection with 25 mg bevacizumab-800CW before bronchoscopy | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Fluorescence molecular imaging during bronchoscopy with bevacizumab-800CW at dose of 15 mg
- interventionNames
- Drug: injection with 15 mg bevacizumab-800CW before bronchoscopy
- type
- EXPERIMENTAL
- label
- Fluorescence molecular imaging during bronchoscopy with bevacizumab-800CW at dose of 25 mg
- interventionNames
- Drug: injection with 25 mg bevacizumab-800CW before bronchoscopy
Primary outcomes (1)
- measure
- Fluorescent signal of malignant lesion versus non-tumorous tissue.
- timeFrame
- Assessed directly during the bronchoscopy procedure
- description
- Comparison of the in vivo fluorescent signal of malignant lesion (pulmonary nodule or lymph node metastasis) versus non-tumorous tissue: The fluorescent signal will be assessed qualitatively (categorical data) and quantitatively (pulmonary nodule: by multi-diameter single fiber reflectance spectroscopy/single-fiber fluorescence spectroscopy (MDSFR/SFF), lymph node metastases: by ultrasound guided needle biopsy single-fiber fluorescence (USNB/SFF)).
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Signed informed consent prior to participation in the study. 2. Age ≥ 18 years. 3. Patient has at least one intrabronchial, near-to-airway located or peripheral pulmonary nodule - with or without pathological lymph nodes - which is considered malignant (independent of its primary origin). 4. Patient is considered fit to undergo a diagnostic and/or therapeutic bronchoscopy (with or without addition of virtual navigation and/or endobronchial ultrasound; including propofol sedation or general anesthesia if either is indicated) to obtain tumor material according to standard care protocols. Exclusion Criteria: 1. History of infusion reactions to bevacizumab. 2. Medical or psychiatric conditions that compromise the patient's ability to give informed consent. 3. Pregnancy or breast feeding.
References
Publications (0)
Data not yet available
No reference posted for this study.